|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Activation of HMGB1 and downstream signaling pathways are contributing factors in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and drug-induced liver injury (DILI), each of which involves sterile inflammation, liver fibrosis, ductular reaction, and hepatic tumorigenesis.
|
31731454 |
2019 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, HMGB1 can produce multiple inflammatory mediators through ER stress, which, in turn, promote liver fibrosis.
|
29959419 |
2018 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we first documented an enrichment of peripheral and intrahepatic HMGB1 signal in hepatitis B virus (HBV)-related liver fibrosis progression, and presented a direct evidence of anatomic proximity of HMGB1 with a-SMA (a marker for HSCs activation) in cirrhotic liver specimens.
|
29907694 |
2018 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
San-Cao Granule () Ameliorates Hepatic Fibrosis through High Mobility Group Box-1 Protein/Smad Signaling Pathway.
|
26688180 |
2018 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, infected mice that were treated with DIC or GZR to inhibit HMGB1 pro-inflammatory activity showed a significant increase in survival and a reduction of over 50% in the area of liver fibrosis.
|
30258438 |
2018 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hmgb1 ablation in hepatocytes (Hmgb1<sup>ΔHep</sup> ) or in myeloid cells (Hmgb1<sup>ΔMye</sup> ) partially protected, whereas ablation in both (Hmgb1<sup>ΔHepΔMye</sup> ) prevented liver fibrosis in vivo.
|
29774570 |
2018 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The injury resistance in the setting of liver fibrosis is accompanied by the inhibition of HMGB1 translocation and release as well as the suppression of HMGB1-related proinflammatory immune responses.
|
28903095 |
2018 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to evaluate the association between serum levels of HMGB1 and liver fibrosis.
|
28885322 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum high mobility group box 1 protein (HMGB1) is a proinflammatory molecule that could potentially serve as a biomarker for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) due to its correlation with degree of liver fibrosis.
|
29095942 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that CA might exert anti-liver fibrosis properties through an HMGB1-related pathway, and the results of the present study showed that CA treatment significantly protected against hepatic fibrosis in a bile duct ligation (BDL) rat model.
|
29403377 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pooled mean difference of HMGB1 in low liver fibrosis patients compared with high liver fibrosis was -125.38 (95% CI: -539.44-288.68, Z=0.59, I2=98%, P=0.55).
|
27973467 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Well-established liver fibrosis along with marked induction of HMGB1 occurred in CCl<sub>4</sub>-injected <i>Opn</i><sup>Hep</sup> transgenic yet it was less in wild type and almost absent in <i>Opn<sup>-/-</sup></i> mice.
|
26818617 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-localization of F4/80, HMGB1, and Col-1 was found in fibrotic livers, indicating the close relationship between KCs, HMGB1 and liver fibrosis.
|
28611518 |
2017 |